WebDoctor Encyclopedia

Article

Aromatase Inhibitors and Tamoxifen

What are aromatase inhibitors and tamoxifen?

Aromatase inhibitors and tamoxifen are hormone (endocrine) therapies used mainly for breast cancer that grows in response to the hormone oestrogen. About three in four breast cancers have oestrogen receptors (they are “ER-positive” or “hormone receptor-positive”). These cancers use oestrogen as a growth signal, so blocking that signal can stop them growing.

The two types of medicine work in different ways:

Medicine How it works Examples
Tamoxifen Blocks oestrogen from attaching to its receptor on breast cancer cells Tamoxifen
Aromatase inhibitors (AIs) Lower the amount of oestrogen the body makes after the menopause Anastrozole, letrozole, exemestane

Both are taken as a daily tablet, usually for 5-10 years after surgery for early breast cancer. They lower the chance of the cancer coming back and of a new cancer developing in the other breast. They are also used to control breast cancer that has spread, and sometimes to prevent breast cancer in women at high risk.

A brief history

Tamoxifen was first developed in the 1960s, oddly enough as a possible contraceptive. It became a breast cancer treatment in the 1970s and is now one of the most widely used cancer medicines in the world. Aromatase inhibitors arrived in the 1990s and were soon shown to work even better than tamoxifen for many postmenopausal women.

1. Key facts at a glance

Feature Details
Type of treatment Hormone therapy
Main use Hormone receptor-positive breast cancer in women and men
How it is given Tablet once a day
Course length Usually 5 years, sometimes up to 10 years
Who gets AIs Mainly postmenopausal women, or premenopausal women with ovarian suppression
Who gets tamoxifen Premenopausal and postmenopausal women, and men
Common side effects Hot flushes, joint pain (AIs), vaginal dryness, mood changes
Serious risks Bone thinning (AIs); blood clots and womb cancer (tamoxifen, rare)

2. How it works

Where oestrogen comes from

Life stage Main source of oestrogen
Before the menopause The ovaries
After the menopause Fat, muscle and other tissues, where the enzyme aromatase converts other hormones into oestrogen
Men Mostly made by aromatase from testosterone

Tamoxifen

Tamoxifen is a selective oestrogen receptor modulator (SERM). In breast tissue, it sits in the oestrogen receptor and blocks it, like a key that fits a lock but does not turn. In some other tissues, such as bone and the lining of the womb, it acts partly like oestrogen. This explains both some benefits, such as helping protect bones after the menopause, and some risks, such as a small increase in womb cancer.

Aromatase inhibitors

AIs block the aromatase enzyme and lower oestrogen levels throughout the body. They work well after the menopause, when the ovaries have stopped producing oestrogen. Before the menopause, the ovaries would simply make more oestrogen, so AIs are only used in younger women together with ovarian suppression (injections or surgery that switch off the ovaries).

3. Who it is for

Conditions treated

Condition Role
Invasive ductal carcinoma Standard for hormone receptor-positive cancers after surgery, and for advanced disease
Invasive lobular carcinoma Almost always hormone receptor-positive; endocrine therapy is central
Tubular carcinoma of the breast Usually hormone receptor-positive with an excellent outlook
Mucinous carcinoma of the breast Often hormone receptor-positive
Ductal carcinoma in situ Sometimes used after surgery to lower the risk of new breast cancer
Lobular carcinoma in situ Can be used to lower future breast cancer risk
Male breast cancer Tamoxifen is the usual first choice
Low-grade serous ovarian carcinoma Letrozole and other hormone treatments are used
Ovarian granulosa cell tumour AIs are sometimes used for recurrent disease

Choosing between them

Situation Usual choice
Postmenopausal women An AI, or tamoxifen followed by an AI
Premenopausal women, lower risk Tamoxifen
Premenopausal women, higher risk Ovarian suppression plus an AI or tamoxifen
Men Tamoxifen; an AI with testosterone suppression if tamoxifen is unsuitable
History of blood clots AI usually preferred
Osteoporosis Tamoxifen may be preferred, or an AI with bone protection

4. Before treatment

Step Why it is done
Confirm hormone receptor status Treatment only helps hormone receptor-positive cancers
Menopausal status Decides which drug can be used
Bone density scan Recommended before starting an AI
Medicines review Some antidepressants can reduce the effect of tamoxifen
Clot risk assessment Before tamoxifen
Contraception plan Tamoxifen can harm an unborn baby

5. What to expect: step by step

Step What happens
1. Starting Usually after surgery, and after chemotherapy or radiotherapy if these are given
2. Daily tablet Take it at the same time each day, with or without food
3. First review Usually after 2-3 months to check side effects
4. Regular follow-up Every 6-12 months, with mammograms each year
5. Possible switch Some women change from tamoxifen to an AI after 2-3 years, or the other way round
6. Decision at 5 years Your team discusses whether to stop or continue for longer

Set a daily reminder on your phone or keep tablets next to something you use every morning.

Ovarian suppression

For premenopausal women who need ovarian suppression, this is usually given as a monthly or three-monthly injection of goserelin or a similar drug. Some women choose surgery to remove the ovaries instead.

Sticking with treatment

Many women find it hard to keep taking a daily tablet for years, especially if side effects are troublesome. Stopping early increases the risk of the cancer returning. If side effects are a problem, talk to your team: switching to a different drug, short breaks or treatments for side effects often help.

6. Side effects and risks

Side effect Tamoxifen Aromatase inhibitors
Hot flushes and night sweats Common Common
Joint and muscle pain Less common Common, sometimes severe
Vaginal dryness Less common Common
Vaginal discharge or bleeding Common; report any bleeding after the menopause Uncommon
Bone thinning Protective after the menopause Increased risk
Blood clots Increased risk Little or no increase
Womb (endometrial) cancer Small increased risk after the menopause No increase
Mood changes Possible Possible
Hair thinning Occasional Occasional
Raised cholesterol Uncommon Possible

Numbers from ATLAS

In the ATLAS trial, women who took tamoxifen for a full decade had a higher risk of blood clots in the lung and of womb cancer. The cumulative risk of womb cancer over years 5-14 was about 3.1% with 10 years of tamoxifen compared with 1.6% in women who stopped at 5 years (Davies et al., 2013).

7. Results and outlook

Study Main finding
EBCTCG meta-analysis, about 32,000 postmenopausal women Five years of an AI lowered recurrence compared with five years of tamoxifen, and 10-year breast cancer mortality was 12.1% versus 14.2% (EBCTCG, 2015)
ATLAS, about 6,800 women with ER-positive cancer Taking tamoxifen for a decade rather than half that time lowered the chance of recurrence and breast cancer death, with most of the benefit seen after year 10 (Davies et al., 2013)
SOFT and TEXT, premenopausal women Adding ovarian suppression to tamoxifen improved 8-year survival, and exemestane plus ovarian suppression gave the lowest recurrence rates, at the cost of more side effects (Francis et al., 2018)

How long to continue

Five years of endocrine therapy is the standard starting point. For women with a higher chance of recurrence, such as those whose cancer had spread to lymph nodes, continuing for 7-10 years may give extra protection. The decision balances the extra benefit against the side effects of longer treatment, and is made together with your team.

A long-lasting benefit

Endocrine therapy for early breast cancer has a “carry-over” effect: its benefit continues for years after the tablets are stopped. This is one reason why women are encouraged to complete the full course.

8. Recovery and aftercare

Managing common side effects

Side effect What can help
Hot flushes Layered clothing, fans, avoiding triggers; some non-hormonal medicines can help
Joint pain Regular exercise, simple painkillers, switching to another AI
Vaginal dryness Non-hormonal moisturisers and lubricants; ask about low-dose vaginal oestrogen
Bone thinning Weight-bearing exercise, calcium, vitamin D and bone-strengthening drugs
Low mood Talking therapies and support groups
Weight gain Balanced diet and regular activity

Emotional wellbeing

Taking a daily tablet can be a constant reminder of cancer, long after other treatment has ended. Some women feel anxious about recurrence; others feel frustrated by side effects that affect work, sleep or relationships. Support groups, counselling and open conversations with your breast care nurse can help you find a way to live well during these years.

Warning signs to report

  • Leg swelling, pain or redness, or sudden breathlessness (possible blood clot, mainly with tamoxifen)
  • Vaginal bleeding after the menopause while on tamoxifen
  • New lumps, bone pain or persistent cough
  • Severe joint pain that stops you from doing daily activities

Follow-up

Check Typical timing
Clinic review Every 6-12 months
Mammogram Every year
Bone density scan Every 1-2 years on an AI
Cholesterol Periodically on an AI

Pregnancy and fertility

Tamoxifen can harm a developing baby, so reliable non-hormonal contraception is needed during treatment and for a few months afterwards. Women who want to become pregnant may be able to pause treatment under specialist guidance; discuss this with your team before stopping.

Prevention in women at high risk

Some women who have never had breast cancer but have a high risk, for example because of a strong family history or a previous diagnosis of lobular carcinoma in situ, may be offered tamoxifen or an aromatase inhibitor to lower their risk. This is called chemoprevention. Treatment usually lasts 5 years, and the decision depends on the balance between expected benefit and side effects.

Combining with other treatments

For some higher-risk early breast cancers, a CDK4/6 inhibitor tablet, such as abemaciclib or ribociclib, is added to hormone therapy for the first few years. In advanced breast cancer, hormone therapy is commonly combined with these drugs as first treatment.

9. Alternatives

Alternative When it is considered
Ovarian suppression alone Rarely used alone
Fulvestrant Advanced breast cancer; an injection that breaks down the oestrogen receptor
CDK4/6 inhibitors Added to hormone therapy for advanced cancer and for some higher-risk early cancers
Oral SERDs Newer oestrogen receptor blockers for advanced cancer, especially with ESR1 mutations
Chemotherapy For higher-risk cancers, in addition to hormone therapy
Prevention options Tamoxifen, raloxifene or an AI for women at high risk

If cancer returns or spreads while on one hormone treatment, switching to another, often combined with a targeted drug, can still be effective.

10. Frequently asked questions

Question Answer
Will I lose my hair? Usually not, although some thinning can occur
Can I take HRT? Usually not, as it may feed the cancer
Do I need to take it for 10 years? It depends on your risk; your team will discuss this
Can men take these drugs? Yes; tamoxifen is often used for male breast cancer
Does grapefruit interact? Ask your pharmacist; it depends on the medicine
Can I drink alcohol? Small amounts are usually fine
What if I miss a dose? Take the next dose as normal; do not double up

11. Questions to ask your care team

  • Should I take tamoxifen or an aromatase inhibitor, and why?
  • Do I need ovarian suppression?
  • How long should I take treatment?
  • What can I do about side effects?
  • Do I need a bone density scan?
  • Will any of my other medicines interact?
  • What should I do if I want to become pregnant?

Resources

  1. Davies, C. et al. (2013) ‘Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial’, The Lancet, 381(9869), pp. 805-816.
  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) ‘Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials’, The Lancet, 386(10001), pp. 1341-1352.
  3. Francis, P.A. et al. (2018) ‘Tailoring adjuvant endocrine therapy for premenopausal breast cancer’, New England Journal of Medicine, 379(2), pp. 122-137.
  4. National Cancer Institute (2026) Hormone Therapy – Breast Cancer Treatment. Available at: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet (Accessed: October 2026).
  5. National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.